3,4-Methylenedioxy-N-methoxyamphetamine
| Clinical data | |
|---|---|
| Other names | 3,4-Methylenedioxy-N-methoxyamphetamine; MDMEO; MDMEOA; MDMeOA; N-Methoxy-MDA |
| Routes of administration | Oral[1] |
| ATC code |
|
| Pharmacokinetic data | |
| Duration of action | Unknown[1] |
| Identifiers | |
| |
| CAS Number | |
| PubChem CID | |
| ChemSpider | |
| UNII | |
| CompTox Dashboard (EPA) | |
| Chemical and physical data | |
| Formula | C11H15NO3 |
| Molar mass | 209.245 g·mol−1 |
| 3D model (JSmol) | |
| |
| |
| (verify) | |
MDMEO, also known as 3,4-methylenedioxy-N-methoxyamphetamine or as N-methoxy-MDA, is a psychoactive drug of the phenethylamine, amphetamine, and MDxx families.[1][2] It is the N-methoxy derivative of MDA.[1][2]
Use and effects
In his book PiHKAL (Phenethylamines I Have Known and Loved, Alexander Shulgin lists MDMEO's dose as greater than 180 mg orally and its duration as unknown.[1][2] It produced few or no effects at tested doses.[1]
Chemistry
Properties
MDMEO may be found as white crystals.[1]
Synthesis
The chemical synthesis of MDMEO has been described.[1]
Society and culture
Legal status
United Kingdom
This substance is a Class A drug in the Drugs controlled by the UK Misuse of Drugs Act.[3]
See also
References
- ^ a b c d e f g h Shulgin, Alexander; Shulgin, Ann (September 1991). PiHKAL: A Chemical Love Story. Berkeley, California: Transform Press. ISBN 0-9630096-0-5. OCLC 25627628.
- ^ a b c Shulgin AT (2003). "Basic Pharmacology and Effects". In Laing RR (ed.). Hallucinogens: A Forensic Drug Handbook. Forensic Drug Handbook Series. Elsevier Science. pp. 67–137. ISBN 978-0-12-433951-4. Archived from the original on 13 July 2025.
- ^ "UK Misuse of Drugs act 2001 Amendment summary". Isomer Design. Archived from the original on 22 October 2017. Retrieved 12 March 2014.